Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

Actinic Keratosis Clinical Trial

Official title:

Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02424305
• Other study ID #: LP0084-1077
• Status: Completed
• Phase: Phase 1
• First received: April 14, 2015
• Last updated: May 1, 2017
• Start date: May 2015
• Est. completion date: July 2015

Study information

• Verified date: May 2017
• Source: LEO Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, uncontrolled, non-randomised multi-centre trial in which 3 parallel groups will be enrolled. The trial includes three active treatment groups. To be eligible for inclusion in this trial, subjects must have at least 15 clinically typical, visible, and discrete actinic keratosis (AKs) on the face, scalp or on the arm within a contiguous area of approximately 250 cm2 of sun-damaged skin.

There will be 3 treatment groups: (1) once daily application of LEO43204 gel 0.018% on the full face for three consecutive days, (2) once daily application of LEO43204 gel 0.1% on the arm on a treatment area of approximately 250 cm2 for three consecutive days and , (3) once daily application of LEO43204 gel 0.037 % on the scalp for three consecutive days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects with 15 or more clinically typical, visible and discrete AKs on either:

• Full face (corresponding to a treatment area of at least 250 cm2). If subjects have a beard they must shave no later than the day before the first drug application.

• A contiguous area of approximately 250 cm2 on the arm between wrist and shoulder.

• Balding scalp (corresponding to a treatment area of approximately 250 cm2). Subjects with sparse hair on the scalp can be enrolled as long as LSR and AK assessments are not compromised.

2. Subject at least 18 years of age.

3. Female subjects of childbearing potential* must be confirmed not pregnant by a negative urine pregnancy test prior to trial treatment.

4. Female subjects of childbearing potential must be willing to use effective contraception at trial entry and until completion.

Exclusion Criteria:

1. Location of the treatment area (full face, full balding scalp, chest, trunk or extremities)

• within 5 cm of an incompletely healed wound.

• within 5 cm of a suspected basal cell carcinoma (BCC) or SCC.

2. Previously assigned treatment in this clinical trial or previously participated in a clinical trial in the LEO 43204 programme.

3. Lesions in the treatment area that have: atypical clinical appearance (e.g. cutaneous horns)and/or, recalcitrant disease (e.g., did not respond to cryotherapy on two previous occasions).

Related Conditions & MeSH terms

• Actinic Keratosis
• Keratosis
• Keratosis, Actinic

Intervention

Drug:
• LEO 43204 gel 0.018%

• LEO 43204 gel 0.1%

• LEO 43204 gel 0.037%

Locations

Country	Name	City	State
United States	Pflugerville Dermatology Clinical Research	Pflugerville	Texas

Sponsors (1)

Lead Sponsor	Collaborator
LEO Pharma

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the plasma concentration versus time curve (AUC) of LEO 43204.		Once daily for 3 days
Primary	Peak Plasma Concentration (Cmax) of LEO 43204.		Once daily for 3 days

External Links

•   Clinical Trials at LEO Pharma